Co-High

Co-High Biotech is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on high-value, challenging targets in oncology and immunology, utilizing a proprietary structure-based drug design platform to create first-in-class or best-in-class medicines. Its lead candidate, CH-01, is a potent and selective HPK1 inhibitor currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Co-High Biotech leverages deep expertise in medicinal chemistry and structural biology to address significant unmet medical needs in the global healthcare market. The company is supported by prominent life science investors and maintains a robust pipeline of preclinical programs targeting key pathways in cancer metabolism and immune evasion.